Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00B02RFS12 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.70 -9.72% 6.50 6.50 6.70 7.60 6.25 7.48 81,439,418 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -1.1 -0.0 - 215

Sareum Share Discussion Threads

Showing 12151 to 12175 of 13625 messages
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older
DateSubjectAuthorDiscuss
21/12/2020
10:19
We don’t seem to see much of justrying1. Perhaps he has given up trying here? You can only win nob of the week so many times.
barkboo
21/12/2020
10:17
true spacedust.
red5
21/12/2020
10:16
manage to get some more just in time on the opening
red5
21/12/2020
10:16
The new strain of c19 may have something to do with thr rise too
spacedust
21/12/2020
09:37
Peeps getting burned on the rise now the dip. Stock markets down too.
georgeo1
21/12/2020
09:03
Their lab trial which is grant funded by UK government will move into humans faster than first thought. Class is safe, baricitinib, we have second gen so safer. Worth at least 10p
monstersound
21/12/2020
09:02
Glaxo are in imho 👌
strongbuy
21/12/2020
09:01
And this: https://www.google.com/amp/s/amp.ft.com/content/424ad1e2-9984-4e10-9ffa-0ed08f4e598b Rolling review of data for drugs to treat unmet needs. SDC1801 treats COVID. This will move quick.
monstersound
21/12/2020
09:00
It has to be more than a punt?
barkboo
21/12/2020
08:57
Thanks hh. Speculation that Glaxo might take a chunk?
pennstreet
21/12/2020
08:51
this - hxxps://www.msn.com/en-gb/money/companies/pharma-giant-glaxosmithkline-set-to-cap-a-100m-spending-spree-with-two-major-drug-deals-either-side-of-atlantic/ar-BB1c4A5R?li=AAwnS0s
horridhenry
21/12/2020
08:46
What's fueling this rise?
pennstreet
21/12/2020
08:36
nice rise today
red5
18/12/2020
18:11
Ok thanks all
red5
18/12/2020
16:38
It was £50k that’s already been paid. He seemed a bit too keen to throw the caveat about delays due to COVID in at the AGM. Personally I think it will push on to February? Let’s see.
norma_stitts
18/12/2020
16:16
I think next week 900k rns will be confirmed. We've already received 500k? Onky a matyer of time til we get the additional 900k. One thing is for sure is that there will be loads of news between now and April.
spacedust
18/12/2020
16:11
“But they may choose to progress it intravenously if they cant solve solubility. In which casey fhay still have to pay. Find out soon eitherway” Let’s use that as an excuse for some Manic Street Preachers? https://m.youtube.com/watch?v=fRiOYL_TpUc
norma_stitts
18/12/2020
16:05
Red5, You have got to do your own research. Would you go into a bookies, pick a horse at random and put a couple of grand on it? No, you would go to the form guide, work out what has the best chance of winning and place a bet on odds which you believe are in you favour. It’s the same here, don’t rely on the posters here, and that includes myself, with their wisdom and insights, do your own research, and when it goes well, give yourselve a pat on the back. When it fails, learn about what you did wrong, and move on. A lot of the guys here have been investing for decades, and the one thing we’re have learnt is that we do our own research and then invest. Never, never rely of others, certainly take I what they say, but always check the facts for yourself. Good Luck my Friend.
curriedquaker
18/12/2020
16:03
But they may choose to progress it intravenously if they cant solve solubility. In which casey fhay still have to pay. Find out soon eitherway
mrsapeslaptop
18/12/2020
15:54
Spacedust, it’s also worth noting that they could’ve paid it sooner if they crack it before the 9 months. The fact that they haven’t could be an indication that it’s not a ‘given’ as some people think?
norma_stitts
18/12/2020
15:51
Red, it’s from the 26th March RNS about the FLT3 licensing deal; Sareum Holdings plc ("Sareum" or the "Company") Sareum Signs Global Licensing Deal for its FLT3+Aurora Kinase Inhibitor Programme with a China-based Specialty Pharma Company Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that it has entered into an agreement (the "Agreement") with a China-based specialty pharmaceutical company (the "Licensee). Under the terms of the Agreement, the Licensee has been granted an exclusive worldwide licence to develop, manufacture and commercialise certain small molecule inhibitors of FLT3+Aurora kinases including Sareum's lead candidate SAR-20293 (together the "Compounds"), which has shown potential in preclinical models of acute myeloid leukaemia (AML) and other leukaemias. The Licensee is principally engaged in research and development, production and sales of innovative drugs, including oncology drugs, in China and is listed on the main market of the Shanghai Stock Exchange. Under the terms of the Agreement, the Licensee will fund all future development activities in relation to the Compounds and has been granted sole rights to market any resulting products worldwide. Sareum will receive an initial upfront payment of approximately £50,000. A further payment of approximately £0.9 million will be payable to Sareum if certain milestones related to the oral bioavailability of the Compounds are achieved within nine months from the date of the Agreement (the "Development Payment"). Sareum will assign certain patents in respect of the Compounds to the Licensee upon receipt of the Development Payment. The Agreement may be terminated with immediate effect if Sareum does not receive the Development Payment within nine months of the date of the Agreement. Sareum will also be entitled to receive a future milestone payment in the event that an Investigational New Drug or equivalent application is made in China or any other country. Under the Agreement, Sareum is also eligible to receive certain revenues from the commercialisation of the products by the Licensee outside of China. In addition, Sareum would be eligible to receive commercialisation revenues relating to their commercialisation should the Licensee execute an on-licence of the Compounds and resulting products to a third party. Since all research and development expenditure is written off as it occurs, in line with standard industry practise, the Compounds covered by the Agreement are held at nil value on Sareum's balance sheet. Sareum was advised and assisted on this agreement by Cambridge (UK)-based technology brokerage Link China Pharma Solutions. Sareum's CEO, Dr Tim Mitchell, commented: "We are delighted with this important global licensing deal for our FLT3+Aurora inhibitor programme, which could generate significant milestone revenue in the next nine months. We believe the Licensee has the resources and expertise to further advance these molecules through the clinic to commercialisation in China. "With this programme now partnered, we are wholly focused on advancing the development of our proprietary TYK2/JAK1 inhibitors through preclinical studies and look forward to providing updates as material milestones are reached."
norma_stitts
18/12/2020
15:45
whats the 900k about sorry to be naive i dont know what you are talking about?
red5
18/12/2020
15:31
I thought the 900k is a given...well 99%. But i hear your concerns about the mighty untouchable China
spacedust
18/12/2020
15:28
Spacedust, it would be far more pragmatic to say that we MAY get £900k soon? It is by no means a given. We couldn’t resolve the solubility issues, nor could HMUBEC over a number of years. A caveat on timescales was also alluded to in the AGM. Not to mention that we’re reliant on one of the most corrupt and immoral nations on Earth actually coughing up.
norma_stitts
18/12/2020
14:59
Red were also due 900k very soon
spacedust
Chat Pages: Latest  497  496  495  494  493  492  491  490  489  488  487  486  Older
ADVFN Advertorial
Your Recent History
LSE
SAR
Sareum
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210619 04:45:52